On September 10, Cooper declined 15.52% overnight, trading at $53.98 per share, with turnover of $3,932.49. The sharp selloff followed a disappointing fiscal Q3 earnings release and a significant downward revision to full-year guidance.

Cooper reported fiscal Q3 adjusted EPS of $1.15, beating the $1.12 consensus, but revenue of $1.066 billion fell short of the $1.098 billion estimate. More critically, the company lowered its full-year fiscal 2026 revenue guidance to $4.23–$4.25 billion, well below the prior range of $4.29–$4.32 billion and the analyst consensus of $4.31 billion. Full-year adjusted EPS guidance was also cut to $4.51–$4.55 from $4.58–$4.66, missing the Street estimate of $4.63. Q4 guidance of $1.05–$1.09 EPS on $1.06–$1.08 billion in revenue likewise trailed expectations of $1.19 and $1.11 billion, respectively.

Additionally, GAAP net income plunged 72.45% year-over-year to $52.9 million. The board announced it would retain CooperSurgical after a strategic review, citing inadequate acquisition offers. A $3 billion buyback expansion and reaffirmed long-term free cash flow targets failed to offset bearish sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)